First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Clinical trial NCT05920135 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05920135
Sponsor: Bridge Biotherapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Start date: 2023-09-11
Primary completion: 2026-08-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.